Can you take Ethionamide with Interferon alfa-2b?

Ethionamide has a major potential interaction with Alcoholism.

Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent. Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism. Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.

Ethionamide has a major potential interaction with Alcoholism.

The use of ethionamide is contraindicated in patients with severe liver damage. Like many other antituberculous agents, ethionamide is hepatotoxic. Transient elevations in bilirubin and serum SGOT (AST) and SGPT (ALT) have been reported in 5% of the patients treated with ethionamide. Hepatitis, with or without jaundice, has also been observed, particularly in patients with diabetes mellitus. Therapy with ethionamide should be administered cautiously in patients with liver disease, a history of alcoholism, or diabetes. Liver function tests should be measured at baseline and monthly during therapy, and ethionamide withdrawn at the first signs or symptoms suggestive of liver damage.

Interferon alfa-2b has a major potential interaction with Arrhythmia.

Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.

Interferon alfa-2b has a major potential interaction with Autoimmune Disorders.

Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis. Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.

Interferon alfa-2b has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression. Leukopenia is the primary manifestation. Thrombocytopenia and anemia occur less frequently. Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression. Clinical monitoring of hematopoietic function is recommended.

Interferon alfa-2b has a major potential interaction with Cardiovascular Conditions and Disorders.

Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.

Interferon alfa-2b has a major potential interaction with Depression.

Interferons (alfa or beta) can induce depression and suicidal behavior. Suicidal attempts and suicides have been reported. Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression. Clinical monitoring of psychological status is recommended.

Ethionamide has a major potential interaction with Diabetes Mellitus.

Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent. Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism. Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.

Ethionamide has a major potential interaction with Diabetes Mellitus.

The use of ethionamide is contraindicated in patients with severe liver damage. Like many other antituberculous agents, ethionamide is hepatotoxic. Transient elevations in bilirubin and serum SGOT (AST) and SGPT (ALT) have been reported in 5% of the patients treated with ethionamide. Hepatitis, with or without jaundice, has also been observed, particularly in patients with diabetes mellitus. Therapy with ethionamide should be administered cautiously in patients with liver disease, a history of alcoholism, or diabetes. Liver function tests should be measured at baseline and monthly during therapy, and ethionamide withdrawn at the first signs or symptoms suggestive of liver damage.

Ethionamide has a moderate potential interaction with Diabetes Mellitus.

The use of ethionamide has occasionally been associated with poor diabetic control. Patients with diabetes mellitus should be monitored more closely during therapy with ethionamide, and their antidiabetic regimen adjusted accordingly.

Interferon alfa-2b has a moderate potential interaction with Diabetes Mellitus.

Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients. Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus. Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.

Interferon alfa-2b has a major potential interaction with Heart Failure.

Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.

Interferon alfa-2b has a major potential interaction with Hyperthyroidism.

Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons. Therapy with interferons should be administered cautiously to patients with thyroid dysfunction. If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued. Clinical monitoring of thyroid function is recommended.

Interferon alfa-2b has a major potential interaction with Ischemic Heart Disease.

Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.

Ethionamide has a major potential interaction with Liver Disease.

The use of ethionamide is contraindicated in patients with severe liver damage. Like many other antituberculous agents, ethionamide is hepatotoxic. Transient elevations in bilirubin and serum SGOT (AST) and SGPT (ALT) have been reported in 5% of the patients treated with ethionamide. Hepatitis, with or without jaundice, has also been observed, particularly in patients with diabetes mellitus. Therapy with ethionamide should be administered cautiously in patients with liver disease, a history of alcoholism, or diabetes. Liver function tests should be measured at baseline and monthly during therapy, and ethionamide withdrawn at the first signs or symptoms suggestive of liver damage.

Ethionamide has a major potential interaction with Liver Disease.

Ethionamide is primarily metabolized by the liver. Patients with liver disease may be at greater risk for adverse effects from ethionamide due to decreased drug clearance. Dosage reductions are recommended in these patients.

Interferon alfa-2b has a major potential interaction with Liver Disease.

Hepatotoxicity, including fatal cases, has been reported in patients treated with interferon alpha. Additionally, the risk of hepatic decompensation and death is increased in patients with cirrhosis. Any patient developing liver function abnormalities during treatment should be monitored closely and treatment should be discontinued if appropriate. Interferon-alfa is contraindicated in patients with autoimmune hepatitis and decompensated liver disease.

Ethionamide has a major potential interaction with Malnourishment.

Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent. Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism. Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.

Interferon alfa-2b has a major potential interaction with Parkinsonism.

Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.

Ethionamide has a major potential interaction with Peripheral Neuropathy.

Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent. Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism. Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.

Interferon alfa-2b has a moderate potential interaction with Peripheral Neuropathy.

Paresthesia and numbness have been reported during interferon therapy. Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.

Interferon alfa-2b has a major potential interaction with Psychosis.

Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.

Interferon alfa-2b has a major potential interaction with Renal Dysfunction.

Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy. Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported. Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction. Renal function should be evaluated in all patients before initiation of interferon- alfa therapy. In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance. A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).

Interferon alfa-2b has a major potential interaction with Seizures.

Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.

Interferon alfa-2b has a moderate potential interaction with Ulcerative Colitis.

Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment. Abdominal pain, bloody diarrhea, and fever are the typical manifestations. Treatment should be discontinued immediately in patients who develop these signs and symptoms. The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.

Interferon alfa-2b has a major potential interaction with Underactive Thyroid.

Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons. Therapy with interferons should be administered cautiously to patients with thyroid dysfunction. If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued. Clinical monitoring of thyroid function is recommended.